News & Media

Nasal Spray Offers Hope For Severely Depressed Patients

By Peggy McCarthy August 13, 2019 Originally published in Connecticut Health I-Team on C-Hit.org. Some Connecticut hospitals and doctors and a clinic are starting to treat severely depressed patients with a new nasal spray called Spravato, touted as the most significant federally approved depression medication since Prozac was approved in 1987. Spravato, which received Food and Drug Administration […]

0 comments

Ketamine isn’t an opioid and treats depression in a unique way, says Johns Hopkins expert

In scientific journal letter, Hopkins psychiatrist Adam Kaplin disputes a study claiming ketamine is an opioid. Ketamine has gotten a bad reputation as an opioid—when there’s plenty of evidence suggesting it isn’t one, say Johns Hopkins experts. They believe this misconception may prevent patients from getting necessary treatment for the kinds of depression that don’t respond […]

0 comments

Evidence shows ketamine is not an opioid and can treat depression easily

Ketamine has gotten a bad rap as an opioid when there’s plenty of evidence suggesting it isn’t one, Johns Hopkins experts say. They believe this reputation may hamper patients from getting necessary treatment for the kinds of depression that don’t respond to typical antidepressants. In a new paper, the researchers clarify the mechanism behind ketamine’s […]

0 comments

Study Finds Ketamine Nasal Spray Effective For Treating Depression: What You Should Know

Ketamine for depression has changed the face of psychiatry.

A new study finds that a nasal spray formulated from the anesthetic ketamine is a safe, fast-acting and effective treatment for treatment-resistant depression. Researchers presented the findings this week at the annual meeting of the American Psychiatric Association. Esketamine, the intranasal formulation of ketamine, recently received FDA approval as a depression treatment when used with an oral antidepressant, based […]

0 comments

Opinion: The New Ketamine-Based Antidepressant Is a Rip-Off

Johnson & Johnson patented a form of the psychedelic with less research and a ridiculous price tag. In a popular and public move, the United States’ Federal Drug Administration recently approved intranasal esketamine, one of the components of the psychedelic ketamine, for treatment-resistant depression. The nasal spray costs nearly $900 per dose—or roughly $7,000 for the first month […]

1 Comment

Relieving Treatment-Resistant Depression By Treating Metabolic Deficiencies

Originally published in Brain & Behavior Magazine, July 2017 An important discovery has been made at the University of Pittsburgh. It raises the prospect that there may be an entirely new way of relieving major depression in people who repeatedly have failed to respond to existing treatments—people at elevated risk for suicide whose lives are often unrelentingly dark […]

2 Comments

Behind the Buzz: How Ketamine Changes the Depressed Patient’s Brain

The anesthetic-cum-party drug restores the ability to make connections among brain cells. The Food and Drug Administration’s approval last month of a depression treatment based on ketamine generated headlines, in part, because the drug represents a completely new approach for dealing with a condition the World Health Organisation has labelled the leading cause of disability […]

0 comments

Ketamine May Relieve Depression By Repairing Damaged Brain Circuits

Ketamine appears to restore faulty connections between brain cells, according to research performed in mice. The anesthetic ketamine can relieve depression in hours and keep it at bay for a week or more. Now scientists have found hints about how ketamine works in the brain. In mice, the drug appears to quickly improve the functioning […]

0 comments

Weekly Ketamine Infusions Show Initial, Repeated Depression Benefits

A new study shows that weekly ketamine infusions are associated with continued and maintained reductions in depressive symptoms among patients with treatment-resistant depression. The findings, which are considered novel among studies assessing ketamine administration for patients with treatment-resistant depression, evidence the promising role the controversial drug could play in psychiatric care. A team of investigators, led […]

0 comments

The FDA accepted a brand new ketamine melancholy drug — right here’s what’s subsequent

For years, ketamine clinics across the country have offered intravenous infusions as a fast-acting treatment for severe depression. But last week, the US Food and Drug Administration approved a version of ketamine, called esketamine, to do the same thing — so what’s the difference and what will this mean for newly interested patients? Ketamine, sometimes […]

0 comments